Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours

Histopathology

Volumn 69, Issue 4, 2016, Pages 560-569

  Hoang, Lien N ^a,b   Lee, Yow Shan ^c   Karnezis, Anthony N ^a   Tessier Cloutier, Basile ^a   Almandani, Noorah ^a   Coatham, Mackenzie ^d   Gilks, C Blake ^a   Soslow, Robert A ^b   Stewart, Colin J R ^e   Köbel, Martin ^f   Lee, Cheng Han ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF ALBERTA   (Canada)

^e KING EDWARD MEMORIAL HOSPITAL   (Australia)

^f CALGARY LABORATORY SERVICES   (Canada)

Author keywords

BRG1; dedifferentiated carcinoma; endometrial cancer; INI1; PAX8; SMARCA4; SMARCB1; undifferentiated carcinoma

Indexed keywords

BRG1 PROTEIN; ESTROGEN RECEPTOR; MISMATCH REPAIR PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR PAX8;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL FEATURE; CONTROLLED STUDY; DEDIFFERENTIATED ENDOMETRIAL CARCINOMA; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UNDIFFERENTIATED CARCINOMA; VERY ELDERLY;

EID: 84987806884     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12989     Document Type: Article

References (21)

1. Silva EG, Deavers MT, Bodurka DC et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int. J. Gynecol. Pathol. 2006; 25; 52–58.
2. Zaino RJ, Carinelli SG, Ellenson LH et al. Tumours of the uterine corpus – epithelial tumours and precursors. In Kurman RJ, Carcangiu ML, Herrington CS, Young RH eds. World Health Organization classification of tumours of female reproductive organs. Lyon: IARC Press, 2014; 125–132.
3. Kuhn E, Ayhan A, Bahadirli-Talbott A et al. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am. J. Surg. Pathol. 2014; 38; 660–665.
4. Tafe LJ, Garg K, Chew I et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod. Pathol. 2010; 23; 781–789.
5. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007; 39; 134–138.
6. Stewart CJ, Crook ML. SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma. Pathology 2015; 47; 439–445.
7. Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 2015; [epub ahead of print PMID 26371430]
8. Ramalingam P, Masand RP, Euscher ED et al. Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. Int. J. Gynecol. Pathol. 2015; [epub ahead of print PMID 26598976]
9. Garg K, Shih K, Barakat R et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am. J. Surg. Pathol. 2009; 33; 1869–1877.
10. Garg K, Leitao MM Jr, Kauff ND et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am. J. Surg. Pathol. 2009; 33; 925–933.
11. Karnezis AN, Hoang LN, Coatham M et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod. Pathol. 2016; 29; 302–314.
12. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 2013; 8; e55119.
13. Masliah-Planchon J, Bieche I, Guinebretiere JM et al. SWI/SNF chromatin remodeling and human malignancies. Annu. Rev. Pathol. 2015; 10; 145–171.
14. Strehl JD, Wachter DL, Fiedler J et al. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Ann. Diagn. Pathol. 2015; 19; 198–202.
15. Hammond ME, Hayes DF, Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 2010; 6; 195–197.
16. Yemelyanova A, Gown AM, Wu LS et al. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations. Int. J. Gynecol. Pathol. 2014; 33; 492–499.
17. Kobel M, Reuss A, Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191–198.
18. Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am. J. Surg. Pathol. 2011; 35; 816–826.
19. Lim D, Ip PP, Cheung AN et al. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am. J. Surg. Pathol. 2015; 39; 1061–1069.
20. Mhawech-Fauceglia P, Yan L, Liu S et al. ER+/PR+/TFF3+/IMP3-immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology 2013; 62; 976–985.
21. Oike T, Ogiwara H, Amornwichet N et al. Chromatin-regulating proteins as targets for cancer therapy. J. Radiat. Res. 2014; 55; 613–628.